MoonLake Immunotherapeutics MLTX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's net income?
- MoonLake Immunotherapeutics (MLTX) reported net income of -$69.71M in Q1 2026.
- How has MoonLake Immunotherapeutics's net income changed year-over-year?
- MoonLake Immunotherapeutics's net income decreased by 71.9% year-over-year, from -$40.56M to -$69.71M.
- What is the long-term trend for MoonLake Immunotherapeutics's net income?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's net income has grown at a 42.4% compound annual growth rate (CAGR), from -$55.96M to -$230.32M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.